# NECTINIUM-2 (NCT07020117)

> A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors

No report yet. It can be ordered.

- Drugs tested: [225Ac]Ac-AKY-1189
- Indication: previously treated locally advanced or metastatic solid tumors

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT07020117
- Phase: PHASE1
- Status: RECRUITING
- Sponsor: Aktis Oncology, Inc.
- Conditions: Urothelial Carcinoma Bladder; Triple Negative Breast Cancer (TNBC); Hormone Receptor Positive Breast Adenocarcinoma; Non Small Cell Lung Cancer; Cervical Adenocarcinoma; Colorectal Adenocarcinoma; Head and Neck Cancer
- Interventions: [225Ac]Ac-AKY-1189 (therapeutic); [64Cu]Cu-AKY-1189 (imaging)
- Enrollment: 150
- Primary outcome: Part 1: Number of Patients with Dose-Limiting Toxicities
- Primary outcome: Part 1: Occurence of Adverse Events by Severity
- Primary outcome: Part 2: Objective Response Rate (ORR)

## Indexed commentary on NECTINIUM-2 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 4 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=nectinium-2-nct07020117